Context Clinical trial results suggest that intracoronary delivery of autologous bone marrow
mononuclear cells (BMCs) may improve left ventricular (LV) function when administered …

Aims Clinical trials suggest that intracoronary delivery of autologous bone marrow-derived
cells (BMCs) 1–7 days post-acute myocardial infarction (AMI) may improve left ventricular …

Context While the delivery of cell therapy after ST-segment elevation myocardial infarction
(STEMI) has been evaluated in previous clinical trials, the influence of the timing of cell …

Background—Intracoronary administration of autologous bone marrow–derived
mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute …

Background Previous studies have shown improvement in left ventricular function after
intracoronary injection of autologous cells derived from bone marrow (BMC) in the acute …

Recent clinical studies have demonstrated that intracoronary infusion of autologous bone
marrow cells (BMC) in conjunction with standard treatment may improve left ventricular …

Several previous studies have demonstrated that administration of autologous bone marrow–
derived mononuclear cells (BMMNCs) improves cardiac function in patients after acute …

Aims Intracoronary administration of autologous bone marrow cells (BMCs) leads to a
modest improvement in cardiac function, but the effect on myocardial viability is unknown …

Background Experimental and clinical studies have suggested that intracoronary infusion of
bone marrow-derived stem/progenitor cells (BMC) may improve left ventricular function after …

Background Pilot trials suggest that the intracoronary administration of autologous
progenitor cells may improve left ventricular function after acute myocardial infarction …